Page last updated: 2024-08-24

telmisartan and ramipril

telmisartan has been researched along with ramipril in 162 studies

Research

Studies (162)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's84 (51.85)29.6817
2010's73 (45.06)24.3611
2020's5 (3.09)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Sleight, P3
Yusuf, S1
Weber, MA3
Hankey, GJ1
Probstfield, JL1
Unger, T1
Matos, L1
Unger, T; Zimmermann, M1
Anderson, C; Hilbrich, L; Mookadam, F; Pogue, J; Ramos, B; Schumacher, H; Sleight, P; Teo, K; Yusuf, S1
de Champlain, J; Lacourcière, Y; Lamarre-Cliche, M; Larochelle, P; Poirier, L1
de Champlain, J; Karas, M; Lacourcière, Y; Lamarre-Cliche, M; Larochelle, P; Poirier, L1
Atkinson, J; Chillon, JM; Dupuis, F; Limiñana, P1
de Champlain, J; Dubé, B; Florescu, M; Karas, M; Lacourcière, Y; Lamarre-Cliche, M; Larochelle, P; LeBlanc, AR; Nadeau, R; Poirier, L1
El-Ali, M; Ioannidis, G; Karabinos, I; Katostaras, T; Kokkinou, V; Koulouris, S; Nanas, I; Stamatelopoulos, S; Symeonides, P; Thalassinos, N; Theodoridis, T; Toutouzas, P; Triantafyllou, K; Vratsista, E1
Amasyali, B; Celik, T; Demirkol, S; Isik, E; Iyisoy, A; Kilic, S; Kose, S; Kursaklioglu, H; Yilmaz, MI1
Bley, S; Drexler, H; Grote, K; Grothusen, C; Luchtefeld, M; Schieffer, B; Selle, T; Tietge, UJ1
Babic, R; Dragicevic, J; Petrovic, D; Petrovic, I; Vasiljevic, Z; Vukovic, N; Zivanovic, B1
Anderson, C1
Gosse, P; Harper, R; Lowe, L; Williams, B1
Davidai, G; Koval, S; Lacourcière, Y; Neutel, JM1
Ioannidis, G; Katritsis, D; Koulouris, S; Symeonides, P; Thalassinos, N; Triantafyllou, K; Vratsista, E1
Delles, C; Fauvel, JP; Mimran, A; Ruilope, LM; Schmieder, RE1
Anderson, C; Gerstein, HC; Held, C; Hilbrich, L; Sleight, P; Teo, K; Yusuf, S; Zhao, F1
Davidai, G; Gosse, P; Lacourcière, Y; Neutel, JM; Schumacher, H; Williams, B1
Baumhäkel, M; Böhm, M; Koon, T; Probstfield, JL; Schmieder, R; Yusuf, S; Zhao, F1
Stoppelhaar, M; Unger, T1
Fitchett, D1
Anderson, C; Copland, I; Dagenais, G; Dyal, L; Pogue, J; Schumacher, H; Sleight, P; Teo, KK; Yusuf, S1
McMurray, JJ1
Heroys, J; Jakobsen, A; Mancia, G; Ralph, A; Rees, T; Shaw, M1
Balduini, CL; Fiore, CE; Granata, A; Pecci, A1
Liakishev, AA1
Hedner, T; Kjeldsen, SE; Narkiewicz, K; Oparil, S2
Krzesinski, JM; Scheen, AJ1
Dahlöf, B; Ritz, E1
Burnier, M; Hess, O; Lüscher, T; Waeber, B1
Banas, B; Büchner, N; Krämer, BK1
Bangalore, S; Messerli, FH; Ram, VS1
van den Meiracker, AH1
Cohn, JN1
Düsing, R; Nitschmann, S1
Bakris, GL; Sarafidis, PA1
Budaj, A; Chaithiraphan, S; Dickstein, K; Dyal, L; Keltai, M; Maggioni, A; Mann, JF; McQueen, M; Metsärinne, K; Oto, A; Parkhomenko, A; Piegas, LS; Pogue, J; Schmieder, RE; Schumacher, H; Svendsen, TL; Teo, KK; Wang, X; Yusuf, S1
Baliga, V; Sharma, A1
Atar, D; Hanley, DF; Serebruany, VL1
Einecke, D1
Shi, XY; Xi, GL; Yuan, HB; Zhu, QF; Zou, Z1
Delles, C; Fauvel, JP; Mimran, A; Raff, U; Ruilope, LM; Schmieder, RE1
Fischer, P; Masnatta, LD; Pesiney, C; Ramirez, AJ; Sanchez, RA1
Hilgers, KF; Ott, C; Raff, U; Ritt, M; Schlaich, MP; Schmieder, RE; Schneider, MP; Schuster, I1
Schindler, C1
Weder, AB1
Anderson, C; Cukierman-Yaffe, T; Gerstein, HC; Hilbrich, L; Jackson, SH; Sleight, P; Teo, K; Yusuf, S; Zhao, F1
Gosse, P; Lacourcière, Y; Neutel, JM; Schumacher, H; Williams, B1
Albert, DH; Banfor, PN; Cox, BF; Davidsen, SK; Franklin, PH; Fryer, RM; Gintant, GA; Larson, KJ; Noonan, WT; Segreti, JA; Tapang, P; Widomski, DL1
Amsterdam, EA; Liebson, PR1
Anderson, C; Cowan, BR; Doughty, RN; Jennings, GL; Krittayaphong, R; Lonn, E; Marwick, TH; Reid, CM; Sanderson, JE; Schmieder, RE; Teo, K; Wadham, AK; Worthley, SG; Young, AA; Yu, CM; Yusuf, S2
Terrosu, P; Verdecchia, P1
Richard Conti, C1
Guthrie, R1
Biasucci, LM; Capogrossi, MC; Crea, F; Dato, I; De Maria, GL; Di Vito, L; Leone, AM; Niccoli, G; Porto, I; Tritarelli, A1
Elliott, HL1
Böhm, M; Fagard, R; Gao, P; Koon, T; Mancia, G; Pogue, J; Redon, J; Schumacher, H; Sleight, P; Verdecchia, P; Weber, M; Williams, B; Yusuf, S1
Mancia, G; Unger, T; Zanchetti, A1
Diener, HC1
Ferrari, R1
Weber, M1
Remuzzi, G; Ruggenenti, P1
Basile, J1
Chen, JH; Fagard, R; Gao, P; Jansky, P; Jennings, G; Kim, JH; Liu, L; Mancia, G; Probstfield, J; Schmieder, RE; Sleight, P; Teo, K; Trimarco, B; Verdecchia, P; Yusuf, S1
Mann, JF; Teo, KK; Tobe, S; Yusuf, S1
Baumhäkel, M; Böhm, M1
Abutaleb, N1
Neldam, S1
Oğuz, A1
Biasucci, LM; Capogrossi, MC; Crea, F; Dato, I; De Maria, GL; Di Vito, L; Leone, AM; Paglia, A; Porto, I; Tritarelli, A1
Hoogwerf, BJ1
Baumhäkel, M; Böhm, M; Dagenais, GR; Diaz, R; Gao, P; Jansky, P; Jennings, GL; Liu, L; Mann, JF; Probstfield, J; Sleight, P; Teo, K; Yusuf, S1
Barrios, V; Echarri, R; Escobar, C1
Capogrosso, C; Di Michele, S; Galzerano, A; Galzerano, D; Gaudio, C; Lama, D; Paparello, P1
de Boer, IH; Pichler, RH1
Budzyn, K; Drummond, GR; Sobey, CG1
Atkinson, J; Capdeville-Atkinson, C; Chillon, JM; Dupuis, F; Limiñana, P; Vincent, JM1
Anantharaman, R; Bhadada, SK; Bhansali, A; Dutta, P; Jayaprakash, P; Kohli, HS; Upreti, V; Walia, R1
Bilo, G; Mancia, G; Parati, G; Schumacher, H1
Pollock, CA; Ritz, E; Schmieder, RE1
Anderson, C; Arima, H; Binbrek, A; Chazova, I; Commerford, P; Dans, A; Dyal, L; Gao, P; Holwerda, N; Paolasso, E; Pogue, J; Schumacher, H; Teo, K; Unger, T; Young, J; Yusuf, S1
Baumhäkel, M; Böhm, M; Mahfoud, F; Werner, C1
Agarwal, S; Dwivedi, A; Gupta, VK; Jain, R; Lukram, O1
Guthrie, RM1
Chaithiraphan, S; Chen, JH; Dans, AL; Gao, P; Jae-Hyung, K; Lisheng, L; Teo, K; Yusoff, K; Yusuf, S; Zhu, J1
Baumhäkel, M; Böhm, M; Kratz, M; Schlimmer, N1
Derosa, G; Destro, M; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A1
Clase, CM; Gao, P; Grosshennig, A; Mann, JF; McQueen, M; Teo, KK; Tobe, SW; Wang, X; Yusuf, S1
Ruilope, LM; Segura, J; Zamorano, JL1
Ruilope, LM1
Liu, LS; Tan, HQ; Teo, KK; Wang, GG; Yu, LT; Zhu, J1
Arfa, O; Czech, T; Ebrahimian, T; Endtmann, C; Fritz, M; Laufs, U; Nickenig, G; Petoumenos, V; Wassmann, K; Wassmann, S; Werner, N1
Godes, M; Krikov, M; Mueller, S; Namsolleck, P; Rumschüssel, K; Schmerbach, K; Steckelings, U; Thoene-Reineke, C; Unger, T; Villringer, A; Wengenmayer, C1
Jennings, G; Liu, GL; Mancia, G; Redon, J; Ryden, L; Schmieder, R; Schumacher, H; Sleight, P; Teo, K; Verdecchia, P; Yusoff, K; Yusuf, S1
Avezum, A; Dans, A; Ferreira, R; Gafni, A; Gao, P; Lamy, A; Teo, K; Tong, W; Wang, X; Young, J; Yusuf, S1
Chalmers, J1
Jöhren, O; Miesel, A; Müller-Fielitz, H; Raasch, W; Vogt, FM1
Böhm, M; Fagard, R; Gao, P; Mancia, G; Pogue, J; Redon, J; Schumacher, H; Sleight, P; Teo, K; Verdecchia, P; Weber, M; Williams, B; Yusoff, K; Yusuf, S1
Anantharaman, R; Bhadada, SK; Bhansali, A; Jayaprakash, P; Kohli, HS; Shanmugasundar, G; Walia, R1
Danser, AH; Maggioni, AP; Menard, J; Mueller, DN; Ruilope, LM; Volpe, M; Waeber, B1
Trenkwalder, P1
Böhm, M; Friedrich, EB; Jagoda, P; Kazakov, A; Laufs, U; Müller, P; Semenov, A1
Hollenberg, NK1
Kjeldsen, SE; Okin, PM1
Binbrek, AS; Chazova, I; Dagenais, G; Dans, AL; Ferreira, R; Gao, P; Healey, J; Holwerda, N; Iacobellis, G; Karatzas, N; Keltai, M; Mancia, G; Sleight, P; Teo, K; Verdecchia, P; Yusuf, S1
Grassi, B; Neumann, I1
Böhm, M; Kappert, K; Schmieder, R; Schumacher, H; Sleight, P; Teo, K; Unger, T; Yusuf, S1
Hocher, B; Kalk, P; Lucht, K; Schmerbach, K; Thoene-Reineke, C; Unger, T; Wengenmayer, C1
Bilo, G; Czuriga, I; Fagard, R; Gao, P; Mancia, G; Parati, G; Polák, M; Redon, J; Ribeiro, JM; Sanchez, R; Sleight, P; Teo, K; Trimarco, B; van Mieghem, W; Verdecchia, P; Yusuf, S1
Middeke, M1
Barzilay, JI; Clase, CM; Gao, P; Mann, JF; Mente, A; Sleight, P; Teo, KK; Yusuf, S1
Agarwal, M; Chugh, PK; Gupta, M; Tekur, U1
Huang, Z; Nyström, T; Olverling, A; Sjöholm, Å1
Anand, SS; Bradford, Y; Brown, NJ; Byrd, JB; Kubo, M; McCarty, CA; Nakamura, Y; Pare, G; Ritchie, M; Ross, S; Teo, KK; Woodard-Grice, A; Zuvich, RL1
Böhm, M; Laufs, U; Schmieder, R; Schumacher, H; Sleight, P; Teo, K; Unger, T; Yusuf, S1
Chang, A; Kramer, H1
Clase, CM; Dehghan, M; Dunkler, D; Gao, P; Heinze, G; Kohl, M; Mann, JF; Oberbauer, R; Teo, KK; Yusuf, S1
Gosse, P; Schumacher, H1
Li, L; Liu, LM; Tan, LL; Zhao, HL1
Clase, C; Dagenais, GR; de Zeeuw, D; Gao, P; Heerspink, HJ; Lonn, E; Mann, JF; Sleight, P; Teo, KT; Yusuf, S1
Anderson, C; Bosch, J; Gao, P; Joseph, PG; Khatib, R; O'Donnell, MJ; Probstfield, JL; Teo, KK; Yusuf, S1
Lackland, DT1
Angeli, F; Gao, P; Mancia, G; Pogue, J; Reboldi, G; Sleight, P; Teo, K; Trimarco, B; Verdecchia, P; Yusuf, S1
Basile, JN; Gradman, AH1
Angeloni, E; Lombardo, P; Pirelli, M; Refice, S; Vitaterna, A1
Anderson, C; Böhm, M; Custodis, F; Diener, HC; Fagard, R; Laufs, U; Leong, D; Lonn, E; Mancia, G; O'Donnell, M; Redon, J; Schmieder, R; Schumacher, H; Sleight, P; Sliwa, K; Teo, K; Unger, T; Yusuf, S1
Anderson, C; Cukierman-Yaffe, T; Gao, P; Gerstein, HC; Teo, K; Yusuf, S1
Chen, CH; Cheng, HM; Hoshide, S; Huang, QF; Kario, K; Park, CG; Park, S; Wang, JG1
Arru, D; Assaretti, S; Baralla, A; Carru, C; Ena, S; Mangoni, AA; Satta, AE; Sotgia, S; Sotgiu, E; Zinellu, A1
Barzilay, J; Clase, CM; Gao, P; Mann, JF; Schmieder, RE; Smyth, A; Teo, KK; Tobe, S; Yusuf, S1
Böhm, M; Lonn, EM; Mahfoud, F; Mancia, G; Mann, JFE; Redon, J; Schmieder, RE; Schumacher, H; Sliwa, K; Teo, KK; Weber, MA; Williams, B; Yusuf, S1
Avorn, J; Fralick, M; Kesselheim, AS; Schneeweiss, S1
Böhm, M; Lonn, E; Mahfoud, F; Mancia, G; Mann, JFE; Redon, J; Schmieder, R; Schumacher, H; Sliwa, K; Teo, KK; Weber, M; Williams, B; Yusuf, S1
Böhm, M; Lonn, EM; Mahfoud, F; Mancia, G; Mann, JFE; Marx, N; Redon, J; Schmieder, RE; Schumacher, H; Sliwa, K; Teo, KK; Weber, MA; Williams, B; Yusuf, S1
AlHabib, KF; Altuntas, Y; Anand, SS; Avezum, A; Chifamba, J; Dans, A; Dehghan, M; Diaz, R; Gupta, R; Iqbal, R; Ismail, N; Kaur, M; Khatib, R; Lear, S; Li, N; Liu, X; Lopez-Jaramillo, P; Mente, A; Mohammadifard, N; Mohan, V; Rangarajan, S; Rosengren, A; Seron, P; Sheridan, P; Smuts, M; Soman, B; Swaminathan, S; Szuba, A; Teo, K; Turbide, G; Wielgosz, A; Yusoff, K; Yusuf, R; Yusuf, S; Yusufali, A1
Advani, A; Advani, SL; Batchu, SN; Kabir, MG; Kaur, H; Klein, T; Liu, Y; Yerra, VG1
Aiglova, R; Cernicek, V; Danek, J; Gloger, V; Lazarova, M; Pavlu, L; Precek, J; Schee, A; Skala, T; Taborsky, M; Vicha, M1
Baptiste, PJ; Clase, C; Cunnington, M; Leyrat, C; Mann, JFE; Schultze, A; Tomlinson, LA; Wing, K; Wong, AYS1
Kassie, GM; Kerr, M; Moffat, A; Pratt, N; Roughead, EE1

Reviews

30 review(s) available for telmisartan and ramipril

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Angiotensin II and trials of cardiovascular outcomes.
    The American journal of cardiology, 2002, Jan-24, Volume: 89, Issue:2A

    Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Clinical Trials as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Ramipril; Survival Rate; Telmisartan; Treatment Outcome

2002
From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
    The American journal of cardiology, 2002, Jan-24, Volume: 89, Issue:2A

    Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Carotid Artery Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Prognosis; Ramipril; Receptor, Angiotensin, Type 1; Telmisartan; Treatment Outcome; Ultrasonography; Ventricular Dysfunction, Left

2002
The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?
    The American journal of cardiology, 2002, Jan-24, Volume: 89, Issue:2A

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chronotherapy; Circadian Rhythm; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Telmisartan; Treatment Outcome

2002
Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE?
    Stroke, 2003, Volume: 34, Issue:2

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Clinical Trials as Topic; Diuretics; Drug Therapy, Combination; Humans; Hypertension; Life Style; Practice Guidelines as Topic; Ramipril; Risk; Risk Factors; Stroke; Telmisartan

2003
How cost-effective are new preventive strategies for cardiovascular disease?
    The American journal of cardiology, 2003, May-22, Volume: 91, Issue:10A

    Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Life Expectancy; Models, Econometric; Ramipril; Survival Analysis; Telmisartan; United States

2003
The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
    The American journal of cardiology, 2003, May-22, Volume: 91, Issue:10A

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Ramipril; Renin-Angiotensin System; Telmisartan

2003
[New possibilities in clinical use of angiotensin II receptor inhibitors].
    Orvosi hetilap, 2003, Dec-07, Volume: 144, Issue:49

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Ramipril; Renin-Angiotensin System; Survival Analysis; Telmisartan; Treatment Outcome

2003
Rationale for double renin-angiotensin-aldosterone system blockade.
    The American journal of cardiology, 2007, Aug-06, Volume: 100, Issue:3A

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Telmisartan

2007
Clinical trial update: focus on the ONTARGET study.
    Vascular health and risk management, 2007, Volume: 3, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Randomized Controlled Trials as Topic; Telmisartan

2007
Cardiac and vascular protection: the potential of ONTARGET.
    Medscape journal of medicine, 2008, Mar-26, Volume: 10 Suppl

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiotonic Agents; Cardiovascular Diseases; Clinical Trials as Topic; Drug Delivery Systems; Drug Therapy, Combination; Humans; Ramipril; Telmisartan; Treatment Outcome

2008
Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials.
    Journal of human hypertension, 2009, Volume: 23, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Enalapril; Humans; Hypertension; Lisinopril; Models, Statistical; Perindopril; Ramipril; Randomized Controlled Trials as Topic; Telmisartan; Treatment Outcome

2009
Recent advances in cardiovascular risk reduction: implications of ONTARGET.
    Clinical cornerstone, 2009, Volume: 9 Suppl 3

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Risk Reduction Behavior; Telmisartan

2009
Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2009, Volume: 27, Issue:5

    Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Female; Humans; Male; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Telmisartan

2009
Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2009, Volume: 27, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Humans; Hypertension; Ramipril; Telmisartan; Treatment Outcome

2009
Lessons learned from the ONTARGET and TRANSCEND trials.
    Current atherosclerosis reports, 2009, Volume: 11, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Ramipril; Randomized Controlled Trials as Topic; Telmisartan; Treatment Outcome; United States

2009
Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:18

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan; Treatment Outcome

2009
Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?
    Future cardiology, 2010, Volume: 6, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases; Humans; Hypertension; Losartan; Ramipril; Risk Factors; Telmisartan; Tetrazoles

2010
[Renin-angiotensin-aldosterone system inhibition and cardiovascular protection].
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2009, Volume: 37 Suppl 6

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Ramipril; Renin-Angiotensin System; Telmisartan

2009
Renin-angiotensin system blockade and cardiovascular and renal protection.
    The American journal of cardiology, 2010, Jan-04, Volume: 105, Issue:1 Suppl

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Drug Therapy, Combination; Humans; Kidney Diseases; Ramipril; Telmisartan

2010
Telmisartan in high-risk cardiovascular patients.
    The American journal of cardiology, 2010, Jan-04, Volume: 105, Issue:1 Suppl

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Humans; Kidney Diseases; Ramipril; Risk Factors; Telmisartan

2010
New standards in hypertension and cardiovascular risk management: focus on telmisartan.
    Vascular health and risk management, 2010, Mar-24, Volume: 6

    Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Calcium Channel Blockers; Cardiovascular Diseases; Cardiovascular System; Humans; Hypertension; Ramipril; Risk Factors; Telmisartan

2010
Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.
    Current diabetes reports, 2010, Volume: 10, Issue:4

    Topics: Albuminuria; Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Benzimidazoles; Benzoates; Diabetic Nephropathies; Humans; Hyperkalemia; Models, Biological; Ramipril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Telmisartan

2010
Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database.
    Journal of hypertension, 2010, Volume: 28, Issue:11

    Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Databases, Factual; Female; Humans; Losartan; Male; Ramipril; Randomized Controlled Trials as Topic; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan

2010
Renal protection in diabetes: lessons from ONTARGET.
    Cardiovascular diabetology, 2010, Oct-01, Volume: 9

    Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Diabetic Nephropathies; Humans; Hypertension, Renal; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan

2010
From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
    Cardiology, 2010, Volume: 117, Issue:3

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cardiovascular System; Disease Progression; Humans; Ramipril; Risk Factors; Telmisartan; Treatment Outcome

2010
Telmisartan for the management of patients at high cardiovascular risk.
    Current medical research and opinion, 2011, Volume: 27, Issue:8

    Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cost of Illness; Heart Failure; Humans; Myocardial Infarction; PubMed; Ramipril; Telmisartan; Time Factors

2011
Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
    Journal of hypertension, 2012, Volume: 30, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Diabetes Complications; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Ramipril; Renin; Renin-Angiotensin System; Telmisartan

2012
Target Blood Pressure in Patients with Diabetes: Asian Perspective.
    Yonsei medical journal, 2016, Volume: 57, Issue:6

    Topics: Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hypotension; Male; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Reference Values; Risk Factors; Stroke; Telmisartan

2016
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    Lancet (London, England), 2017, Jun-03, Volume: 389, Issue:10085

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Female; Follow-Up Studies; Hospitalization; Humans; Hypertension; Hypotension; Male; Middle Aged; Multicenter Studies as Topic; Ramipril; Randomized Controlled Trials as Topic; Telmisartan

2017

Trials

57 trial(s) available for telmisartan and ramipril

ArticleYear
Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.
    Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:5

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Germany; Heart Diseases; Humans; Hypertension; Prognosis; Ramipril; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Risk Reduction Behavior; Telmisartan; Treatment Outcome

2004
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmi
    American heart journal, 2004, Volume: 148, Issue:1

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Humans; Middle Aged; Patient Selection; Ramipril; Randomized Controlled Trials as Topic; Research Design; Telmisartan

2004
A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension.
    Blood pressure monitoring, 2004, Volume: 9, Issue:5

    Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Female; Humans; Hypertension; Male; Middle Aged; Ramipril; Renin; Telmisartan; Therapeutic Equivalency

2004
Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives.
    American journal of hypertension, 2005, Volume: 18, Issue:1

    Topics: Adult; Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Calcium Channel Blockers; Circadian Rhythm; Female; Humans; Hyperaldosteronism; Hypertension; Male; Middle Aged; Posture; Prospective Studies; Ramipril; Reference Values; Renin; Renin-Angiotensin System; Telmisartan; Treatment Outcome

2005
The ONTARGET/TRANSCEND Trial Programme: baseline data.
    Acta diabetologica, 2005, Volume: 42 Suppl 1

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Female; Humans; Hypertension; Male; Prospective Studies; Ramipril; Telmisartan

2005
Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients.
    Journal of hypertension, 2005, Volume: 23, Issue:6

    Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Epinephrine; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Norepinephrine; Ramipril; Renin-Angiotensin System; Telmisartan; Treatment Outcome

2005
The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study.
    Clinical cardiology, 2005, Volume: 28, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Ramipril; Stroke Volume; Telmisartan; Treatment Outcome

2005
Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients.
    The Journal of international medical research, 2005, Volume: 33 Suppl 1

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Carotid Arteries; Drug Therapy, Combination; Echocardiography, Doppler; Female; Humans; Hypertension; Male; Middle Aged; Muscle, Smooth, Vascular; Ramipril; Retrospective Studies; Telmisartan; Time Factors; Tunica Intima; Tunica Media; Ventricular Remodeling

2005
Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme.
    The Journal of international medical research, 2005, Volume: 33 Suppl 1

    Topics: Administration, Oral; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; Middle Aged; Natriuretic Peptide, Brain; Patient Selection; Ramipril; Research Design; Telmisartan; Time Factors

2005
The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I).
    Journal of hypertension, 2006, Volume: 24, Issue:1

    Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Cough; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Ramipril; Single-Blind Method; Telmisartan; Time Factors

2006
A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.
    American journal of hypertension, 2006, Volume: 19, Issue:1

    Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Female; Humans; Hypertension; Longitudinal Studies; Male; Middle Aged; Ramipril; Single-Blind Method; Telmisartan

2006
Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study.
    European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology, 2007, Volume: 8, Issue:6

    Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Flow Velocity; Cardiomyopathies; Cross-Over Studies; Diabetes Complications; Double-Blind Method; Echocardiography, Doppler; Female; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Ramipril; Statistics, Nonparametric; Telmisartan; Treatment Outcome

2007
Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes.
    Diabetes care, 2007, Volume: 30, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Flow Velocity; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Female; Humans; Hypertension; Male; Middle Aged; Nitric Oxide; Ramipril; Renal Circulation; Telmisartan

2007
Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.
    Circulation, 2007, Mar-20, Volume: 115, Issue:11

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Glucose; Diabetes Complications; Drug Therapy, Combination; Fasting; Female; Heart Failure; Hospitalization; Humans; Hyperglycemia; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Ramipril; Risk Factors; Telmisartan

2007
The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials.
    Blood pressure monitoring, 2007, Volume: 12, Issue:3

    Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Asian People; Benzimidazoles; Benzoates; Black People; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Female; Humans; Hypertension; Male; Middle Aged; Ramipril; Telmisartan; Time Factors; White People

2007
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telm
    American heart journal, 2007, Volume: 154, Issue:1

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Erectile Dysfunction; Global Health; Humans; Male; Middle Aged; Multivariate Analysis; Patient Satisfaction; Prospective Studies; Ramipril; Risk Factors; Telmisartan

2007
Telmisartan, ramipril, or both in patients at high risk for vascular events.
    The New England journal of medicine, 2008, Apr-10, Volume: 358, Issue:15

    Topics: Aged; Angioedema; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Creatinine; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Ramipril; Risk; Telmisartan

2008
[Telmisartan, ramipril, or both in patients at high risk for vascular events. Results of the ONTARGET trial].
    Kardiologiia, 2008, Volume: 48, Issue:5

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Drug Therapy, Combination; Female; Global Health; Humans; Incidence; Male; Peripheral Vascular Diseases; Ramipril; Risk Factors; Telmisartan; Treatment Outcome

2008
[ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events].
    Revue medicale de Liege, 2008, Volume: 63, Issue:4

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Complications; Drug Therapy, Combination; Humans; Ramipril; Risk Factors; Telmisartan; Treatment Outcome; Vascular Diseases

2008
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
    Lancet (London, England), 2008, Aug-16, Volume: 372, Issue:9638

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Creatinine; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney; Middle Aged; Proteinuria; Ramipril; Telmisartan

2008
Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
    Journal of the Indian Medical Association, 2008, Volume: 106, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biomarkers; Female; Humans; Hypertension; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Ramipril; Telmisartan

2008
Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives.
    Journal of hypertension, 2008, Volume: 26, Issue:12

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; C-Reactive Protein; Cross-Over Studies; Female; Humans; Hypertension; Insulin Resistance; Lipids; Male; Oxidative Stress; PPAR gamma; Ramipril; Renin; Salt Tolerance; Telmisartan

2008
Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.
    Journal of human hypertension, 2009, Volume: 23, Issue:9

    Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Circadian Rhythm; Female; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Ramipril; Telmisartan

2009
Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk.
    Preventive cardiology, 2009,Winter, Volume: 12, Issue:1

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Global Health; Humans; Incidence; Male; Ramipril; Risk Factors; Telmisartan; Treatment Outcome

2009
The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2009, Volume: 98, Issue:7

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Protocols; Double-Blind Method; Drug Therapy, Combination; Female; Heart Ventricles; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Quality Control; Ramipril; Reproducibility of Results; Retrospective Studies; Stroke Volume; Telmisartan; Treatment Outcome; Ventricular Dysfunction, Left

2009
Comparison of the effects of ramipril versus telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome.
    The American journal of cardiology, 2009, Jun-01, Volume: 103, Issue:11

    Topics: Acute Coronary Syndrome; Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; C-Reactive Protein; Endothelium, Vascular; Female; Flow Cytometry; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Prospective Studies; Ramipril; Stem Cells; Telmisartan

2009
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.
    Journal of hypertension, 2009, Volume: 27, Issue:7

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; Prognosis; Ramipril; Telmisartan; Treatment Outcome

2009
Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment
    Circulation, 2009, Oct-06, Volume: 120, Issue:14

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diastole; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; Electrocardiography; Female; Humans; Hypertrophy, Left Ventricular; Male; Odds Ratio; Placebos; Prevalence; Proportional Hazards Models; Ramipril; Regression Analysis; Systole; Telmisartan

2009
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
    The American journal of cardiology, 2009, Dec-01, Volume: 104, Issue:11

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Benzimidazoles; Benzoates; Diabetes Complications; Drug Therapy, Combination; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; Male; Ramipril; Survival Analysis; Telmisartan; Treatment Outcome; Ventricular Dysfunction, Left

2009
Differential levels of circulating progenitor cells in acute coronary syndrome patients with a first event versus patients with recurring events.
    International journal of cardiology, 2011, May-19, Volume: 149, Issue:1

    Topics: AC133 Antigen; Acute Coronary Syndrome; Aged; Angiotensin-Converting Enzyme Inhibitors; Antigens, CD; Antigens, CD34; Benzimidazoles; Benzoates; C-Reactive Protein; Female; Flow Cytometry; Glycoproteins; Hematopoietic Stem Cells; Humans; Linear Models; Male; Middle Aged; Peptides; Prospective Studies; Ramipril; Recurrence; Telmisartan

2011
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoler
    Circulation, 2010, Mar-30, Volume: 121, Issue:12

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Erectile Dysfunction; Humans; Male; Mortality; Predictive Value of Tests; Ramipril; Telmisartan; Treatment Outcome

2010
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
    The Lancet. Neurology, 2011, Volume: 10, Issue:1

    Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cognition Disorders; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mental Status Schedule; Neuropsychological Tests; Odds Ratio; Ramipril; Renin-Angiotensin System; Telmisartan; Treatment Outcome

2011
In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events.
    PloS one, 2010, Dec-21, Volume: 5, Issue:12

    Topics: Angiotensin-Converting Enzyme Inhibitors; Asia; Benzimidazoles; Benzoates; Body Mass Index; Cardiovascular Diseases; Double-Blind Method; Ethnicity; Humans; Patient Compliance; Placebos; Ramipril; Risk; Telmisartan; Treatment Outcome

2010
Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation.
    Journal of cardiovascular pharmacology and therapeutics, 2012, Volume: 17, Issue:1

    Topics: Aged; Atrial Fibrillation; Benzimidazoles; Benzoates; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Male; Metabolic Syndrome; Prospective Studies; Ramipril; Secondary Prevention; Severity of Illness Index; Telmisartan; Treatment Outcome

2012
Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Circulation, 2011, Mar-15, Volume: 123, Issue:10

    Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Creatinine; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Heart Failure; Heart Rate; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Ramipril; Stroke; Telmisartan; Treatment Outcome

2011
Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
    Chinese medical journal, 2011, Volume: 124, Issue:12

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; China; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Ramipril; Telmisartan

2011
Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration.
    Hypertension (Dallas, Tex. : 1979), 2011, Volume: 58, Issue:3

    Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Apolipoproteins E; Apoptosis; Benzimidazoles; Benzoates; Blood Vessels; Bone Marrow Transplantation; Cell Count; Cells, Cultured; Coronary Artery Disease; Double-Blind Method; Endothelial Cells; Female; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Ramipril; Receptor, Angiotensin, Type 1; Regeneration; Stem Cells; Telmisartan; Vasoconstrictor Agents

2011
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).
    Circulation, 2011, Oct-18, Volume: 124, Issue:16

    Topics: Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Guidelines as Topic; Humans; Incidence; Kidney Diseases; Middle Aged; Ramipril; Risk; Stroke; Telmisartan

2011
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).
    Journal of the American College of Cardiology, 2012, Jan-03, Volume: 59, Issue:1

    Topics: Aged; Benzimidazoles; Benzoates; Blood Pressure Determination; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Hypotension; Kaplan-Meier Estimate; Male; Middle Aged; Patient Safety; Ramipril; Reference Values; Risk Assessment; Survival Rate; Telmisartan; Treatment Outcome

2012
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoleran
    Journal of hypertension, 2012, Volume: 30, Issue:5

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anthropometry; Atrial Fibrillation; Benzimidazoles; Benzoates; Body Mass Index; Cardiovascular Diseases; Diabetes Complications; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Male; Middle Aged; Placebos; Ramipril; Risk; Risk Factors; Stroke; Telmisartan; Vitamin K

2012
[Critically appraised article].
    Revista medica de Chile, 2012, Volume: 140, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Middle Aged; Multicenter Studies as Topic; Proteinuria; Ramipril; Telmisartan

2012
Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combinatio
    Circulation, 2012, Aug-21, Volume: 126, Issue:8

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Ramipril; Research Design; Risk Assessment; Risk Factors; Sex Distribution; Sex Factors; Stroke; Telmisartan

2012
Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).
    Hypertension (Dallas, Tex. : 1979), 2012, Volume: 60, Issue:6

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Therapy, Combination; Female; Humans; Hypertension; Longitudinal Studies; Male; Middle Aged; Ramipril; Telmisartan; Treatment Outcome

2012
Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures.
    Clinical journal of the American Society of Nephrology : CJASN, 2013, Volume: 8, Issue:2

    Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Fractures, Bone; Glomerular Filtration Rate; Hip Fractures; Humans; Pelvic Bones; Prospective Studies; Ramipril; Risk Factors; Telmisartan; Time Factors

2013
Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema.
    Pharmacogenetics and genomics, 2013, Volume: 23, Issue:9

    Topics: Angioedema; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Black or African American; Double-Blind Method; Drug Therapy, Combination; ETS Translocation Variant 6 Protein; Genome-Wide Association Study; Humans; Isoenzymes; Neprilysin; Polymorphism, Single Nucleotide; Protein Kinase C; Protein Kinase C-theta; Proto-Oncogene Proteins c-ets; Ramipril; Repressor Proteins; Telmisartan; White People

2013
Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease.
    American heart journal, 2013, Volume: 166, Issue:2

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Ramipril; Risk; Telmisartan

2013
Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.
    JAMA internal medicine, 2013, Oct-14, Volume: 173, Issue:18

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Diet; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Feeding Behavior; Female; Follow-Up Studies; Global Health; Glomerular Filtration Rate; Humans; Incidence; Male; Middle Aged; Prospective Studies; Ramipril; Renal Insufficiency, Chronic; Risk Factors; Telmisartan; Time Factors

2013
Effect of telmisartan vs. ramipril on 'dipping' status and blood pressure variability: pooled analysis of the PRISMA studies.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2014, Volume: 37, Issue:2

    Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Body Mass Index; Body Weight; Circadian Rhythm; Female; Humans; Hypertension; Male; Meta-Analysis as Topic; Middle Aged; Ramipril; Retrospective Studies; Telmisartan

2014
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    European journal of preventive cardiology, 2014, Volume: 21, Issue:3

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Creatinine; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; Humans; Hyperkalemia; Hypertension; Hypokalemia; Kidney; Kidney Diseases; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Nonlinear Dynamics; Odds Ratio; Potassium; Proportional Hazards Models; Ramipril; Renal Dialysis; Renin-Angiotensin System; Risk Assessment; Risk Factors; Stroke; Telmisartan; Time Factors; Treatment Outcome

2014
The mini-mental state examination, clinical factors, and motor vehicle crash risk.
    Journal of the American Geriatrics Society, 2014, Volume: 62, Issue:8

    Topics: Accidents, Traffic; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Automobile Driving; Benzimidazoles; Benzoates; Cardiovascular Diseases; Dementia; Diabetes Complications; Female; Humans; Male; Neuropsychological Tests; Predictive Value of Tests; Prospective Studies; Ramipril; Risk; Telmisartan

2014
Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease.
    Hypertension (Dallas, Tex. : 1979), 2015, Volume: 65, Issue:1

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Coronary Artery Disease; Diastole; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Myocardial Infarction; Ramipril; Stroke; Systole; Telmisartan; Time Factors; Treatment Outcome

2015
Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies.
    The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:7

    Topics: Aged; Aged, 80 and over; Aging; Benzimidazoles; Benzoates; Cardiovascular Diseases; Chronic Disease; Cognition Disorders; Dementia; Disabled Persons; Female; Glucose Metabolism Disorders; Humans; Male; Middle Aged; Ramipril; Risk Factors; Telmisartan

2015
Effects of Ramipril and Telmisartan on Plasma Concentrations of Low Molecular Weight and Protein Thiols and Carotid Intima Media Thickness in Patients with Chronic Kidney Disease.
    Disease markers, 2016, Volume: 2016

    Topics: Aged; Antihypertensive Agents; Benzimidazoles; Benzoates; Carotid Arteries; Cysteine; Drug Combinations; Female; Homocysteine; Humans; Male; Middle Aged; Ramipril; Renal Insufficiency, Chronic; Telmisartan; Tunica Intima

2016
Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
    Kidney international, 2017, Volume: 91, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Disease Progression; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hemodynamics; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Odds Ratio; Ramipril; Renin-Angiotensin System; Risk Factors; Telmisartan; Time Factors; Treatment Outcome

2017
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
    European heart journal, 2018, 09-01, Volume: 39, Issue:33

    Topics: Aged; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Ramipril; Risk Assessment; Single-Blind Method; Stroke; Telmisartan; Treatment Outcome

2018
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.
    European heart journal, 2019, 07-01, Volume: 40, Issue:25

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Determination; Cardiovascular Diseases; Case-Control Studies; Diabetes Mellitus; Diastole; Drug Therapy, Combination; Heart Failure; Hospitalization; Humans; Hypertension; Myocardial Infarction; Peripheral Arterial Disease; Ramipril; Retrospective Studies; Risk Factors; Stroke; Systole; Telmisartan

2019
Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries.
    The American journal of clinical nutrition, 2020, 04-01, Volume: 111, Issue:4

    Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Eggs; Female; Humans; Lipids; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Ramipril; Telmisartan

2020

Other Studies

75 other study(ies) available for telmisartan and ramipril

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
[Preventing cardiovascular diseases. Discovering the optimal approach].
    MMW Fortschritte der Medizin, 2001, Oct-11, Volume: 143, Issue:41

    Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Coronary Artery Disease; Coronary Vessels; Drug Therapy, Combination; Humans; Ramipril; Randomized Controlled Trials as Topic; Telmisartan

2001
[Improved protection of heart and kidneys in the hypertensive patient. ACE inhibitor and AT1 blocker combined?].
    MMW Fortschritte der Medizin, 2003, Jun-05, Volume: 145, Issue:23

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hypertension; Hypertrophy, Left Ventricular; Ramipril; Renal Insufficiency; Telmisartan

2003
[Therapy of hypertension. Lasting organ protection moves into the foreground].
    MMW Fortschritte der Medizin, 2003, Nov-20, Volume: 145, Issue:47

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Myocardial Infarction; Ramipril; Receptor, Angiotensin, Type 1; Stroke; Telmisartan; Treatment Outcome

2003
[Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].
    MMW Fortschritte der Medizin, 2003, Dec-18, Volume: 145, Issue:51-52

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Complications; Drug Therapy, Combination; Humans; Myocardial Infarction; Placebos; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan; Time Factors

2003
Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats.
    Journal of hypertension, 2005, Volume: 23, Issue:5

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Arterioles; Benzimidazoles; Benzoates; Cerebral Arteries; Cerebrovascular Circulation; Homeostasis; Hypertension; Male; Ramipril; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Telmisartan; Vasodilation

2005
Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus.
    The American journal of cardiology, 2005, Jun-01, Volume: 95, Issue:11

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Oxidation-Reduction; Ramipril; Telmisartan

2005
Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis.
    Atherosclerosis, 2005, Volume: 182, Issue:1

    Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Benzimidazoles; Benzoates; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interleukin-10; Interleukin-6; Macrophages; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Monocytes; Pyrroles; Ramipril; Renin-Angiotensin System; Telmisartan

2005
[In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
    MMW Fortschritte der Medizin, 2006, Jun-29, Volume: 148, Issue:26

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypertension; Metabolic Syndrome; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan; Time Factors

2006
[Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection].
    MMW Fortschritte der Medizin, 2007, Dec-06, Volume: 149, Issue:49-50

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Telmisartan

2007
ACE inhibitors in cardiovascular disease--unbeatable?
    The New England journal of medicine, 2008, Apr-10, Volume: 358, Issue:15

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Ramipril; Research Design; Telmisartan; Tetrazoles; Valine; Valsartan

2008
Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome).
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:8

    Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cataract; Female; Hearing Loss, Sensorineural; Humans; Kidney Diseases; Losartan; Male; Molecular Motor Proteins; Mutation; Myosin Heavy Chains; Proteinuria; Ramipril; Renin-Angiotensin System; Syndrome; Telmisartan; Thrombocytopenia

2008
ONTARGET: questions asked, questions answered.
    Journal of clinical hypertension (Greenwich, Conn.), 2008, Volume: 10, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypertension; Multicenter Studies as Topic; Ramipril; Randomized Controlled Trials as Topic; Telmisartan; Treatment Outcome

2008
[What is better here: ACE inhibitor or AT1 blocker?].
    MMW Fortschritte der Medizin, 2008, Apr-17, Volume: 150, Issue:16

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Ramipril; Randomized Controlled Trials as Topic; Telmisartan

2008
A stunning day in hypertension research - Results of ONTARGET, ACCOMPLISH and HYVET.
    Blood pressure, 2008, Volume: 17, Issue:2

    Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Benzimidazoles; Benzoates; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hypertension; Indapamide; Perindopril; Ramipril; Telmisartan

2008
A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction.
    Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5 Suppl 1

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Body Size; Cardiovascular Diseases; Humans; Life Style; Metabolic Syndrome; Obesity; Ramipril; Renin-Angiotensin System; Risk Assessment; Risk Factors; Telmisartan

2008
[Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].
    Praxis, 2008, May-14, Volume: 97, Issue:10

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Multicenter Studies as Topic; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Telmisartan

2008
Telmisartan, ramipril, or both in patients at high risk of vascular events.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus; Drug Therapy, Combination; Humans; Ramipril; Telmisartan

2008
Telmisartan, ramipril, or both in patients at high risk of vascular events.
    The New England journal of medicine, 2008, Jul-24, Volume: 359, Issue:4

    Topics: Angioedema; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypotension; Ramipril; Telmisartan

2008
[No advantage of the combination of ACE-inhibition and angiotensin receptor blockade in patients with high cardiovascular risk].
    Nederlands tijdschrift voor geneeskunde, 2008, Jun-14, Volume: 152, Issue:24

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Ramipril; Telmisartan; Treatment Outcome

2008
Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
    Nature clinical practice. Cardiovascular medicine, 2008, Volume: 5, Issue:9

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atherosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Disease Progression; Drug Therapy, Combination; Humans; Ramipril; Randomized Controlled Trials as Topic; Research Design; Telmisartan; Treatment Outcome

2008
[ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].
    Der Internist, 2008, Volume: 49, Issue:9

    Topics: Aged; Angioedema; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypotension; Ramipril; Risk Assessment; Risk Factors; Telmisartan

2008
Renin-angiotensin blockade and kidney disease.
    Lancet (London, England), 2008, Aug-16, Volume: 372, Issue:9638

    Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Ramipril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Telmisartan

2008
Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Cerebrovascular diseases (Basel, Switzerland), 2008, Volume: 26, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Clinical Trials, Phase IV as Topic; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Randomized Controlled Trials as Topic; Stroke; Telmisartan; Treatment Outcome

2008
[ONTARGET, PROFESS, TRANSCEND large scale studies. AT1 blockers: evidence based advantage, but less than expected].
    MMW Fortschritte der Medizin, 2008, Sep-18, Volume: 150, Issue:38

    Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Evidence-Based Medicine; Follow-Up Studies; Humans; Multicenter Studies as Topic; Ramipril; Randomized Controlled Trials as Topic; Telmisartan

2008
Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes.
    American journal of hypertension, 2008, Volume: 21, Issue:12

    Topics: Adiponectin; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biomarkers; Blood Pressure; Cohort Studies; Confidence Intervals; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypertension, Renal; Male; Middle Aged; Ramipril; Telmisartan

2008
Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009, Volume: 53, Issue:2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Hypertension; Kidney; Male; Middle Aged; Nitric Oxide; p-Aminohippuric Acid; Ramipril; Renal Plasma Flow; Telmisartan; Vascular Resistance

2009
ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Therapeutic advances in cardiovascular disease, 2008, Volume: 2, Issue:4

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Kidney Diseases; Ramipril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Telmisartan

2008
ONTARGET: How much RAS inhibition is enough?
    Current hypertension reports, 2009, Volume: 11, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Humans; Kidney Diseases; Ramipril; Renin-Angiotensin System; Telmisartan

2009
Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme.
    Diabetes research and clinical practice, 2009, Volume: 83, Issue:3

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Glucose; Cardiovascular Diseases; Cognition; Cognition Disorders; Cross-Sectional Studies; Depression; Diabetes Mellitus; Diabetic Angiopathies; Drug Therapy, Combination; Female; Glucose Intolerance; Humans; Male; Middle Aged; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Telmisartan

2009
ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
    Blood pressure, 2009, Volume: 18, Issue:1-2

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Comorbidity; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; Ramipril; Renal Insufficiency; Risk; Stroke; Telmisartan; Treatment Outcome

2009
Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growt
    The Journal of pharmacology and experimental therapeutics, 2009, Volume: 329, Issue:3

    Topics: Acrylates; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationship, Drug; Enalapril; Humans; Imidazoles; Indazoles; Lisinopril; Male; Mice; Mice, SCID; Neoplasms; Nifedipine; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Ramipril; Rats; Rats, Sprague-Dawley; Telmisartan; Thiophenes; Xenograft Model Antitumor Assays

2009
[The ONTARGET trial].
    Giornale italiano di cardiologia (2006), 2009, Volume: 10, Issue:2

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Research Design; Risk Factors; Telmisartan; Treatment Outcome

2009
Clinical practice guides.
    Clinical cardiology, 2009, Volume: 32, Issue:4

    Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Data Interpretation, Statistical; Humans; Myocardial Ischemia; Ramipril; Randomized Controlled Trials as Topic; Statistics as Topic; Telmisartan

2009
Focus on the ONTARGET results.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2009, Volume: 27, Issue:2

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Female; Humans; Male; Ramipril; Renin-Angiotensin System; Telmisartan

2009
Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2009, Volume: 27, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Humans; Hypertension; Ramipril; Renin-Angiotensin System; Risk Factors; Telmisartan

2009
Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2009, Volume: 27, Issue:5

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Ramipril; Retrospective Studies; Risk Factors; Telmisartan

2009
Cardiovascular protection: a breakthrough for high-risk patients?
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2009, Volume: 27, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Renin-Angiotensin System; Risk Factors; Telmisartan

2009
Proteinuria: Is the ONTARGET renal substudy actually off target?
    Nature reviews. Nephrology, 2009, Volume: 5, Issue:8

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Creatinine; Diabetes Mellitus; Disease Progression; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Kidney; Multicenter Studies as Topic; Proteinuria; Ramipril; Randomized Controlled Trials as Topic; Telmisartan

2009
Is therapy of people with chronic kidney disease ONTARGET?
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Chronic Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Kidney Diseases; Ramipril; Telmisartan; Treatment Outcome

2010
ONTARGET should not be over interpreted.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, Volume: 25, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Chronic Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glomerular Filtration Rate; Humans; Kidney Diseases; Ramipril; Telmisartan; Treatment Outcome

2010
New data on ONTARGET: more confusion?
    Journal of clinical hypertension (Greenwich, Conn.), 2010, Volume: 12, Issue:3

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Multicenter Studies as Topic; Ramipril; Randomized Controlled Trials as Topic; Telmisartan

2010
Reduced cerebrovascular remodeling and functional impairment in spontaneously hypertensive rats following combined treatment with suboptimal doses of telmisartan and ramipril: is less really more?
    Journal of hypertension, 2010, Volume: 28, Issue:7

    Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Brain Ischemia; Cerebral Arteries; Drug Therapy, Combination; Hypertension; Male; Ramipril; Random Allocation; Rats; Rats, Inbred SHR; Telmisartan; Vasodilation

2010
Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat.
    Journal of hypertension, 2010, Volume: 28, Issue:7

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arterioles; Benzimidazoles; Benzoates; Blood Pressure; Cerebrovascular Circulation; Drug Therapy, Combination; Hypertension; Male; Ramipril; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Telmisartan

2010
Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy.
    The Indian journal of medical research, 2010, Volume: 132

    Topics: Albumins; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Drug Combinations; Female; Humans; Male; Potassium; Ramipril; Statistics, Nonparametric; Telmisartan

2010
Simultaneous determination of ramipril, ramiprilat and telmisartan in human plasma using liquid chromatography tandem mass spectrometry.
    Talanta, 2011, Jan-15, Volume: 83, Issue:3

    Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Chemical Analysis; Chromatography, Liquid; Humans; Ramipril; Tandem Mass Spectrometry; Telmisartan; Time Factors

2011
Where does the evidence lead us for the proper use of angiotensin II inhibitors in the management of cardiovascular disease?
    Cardiology, 2010, Volume: 117, Issue:3

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cardiovascular System; Humans; Ramipril; Renin-Angiotensin System; Telmisartan

2010
Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis.
    British journal of pharmacology, 2011, Volume: 163, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Atherosclerosis; Benzimidazoles; Benzoates; Blood Pressure; Cholesterol; Drug Therapy, Combination; Endothelium, Vascular; Erectile Dysfunction; Free Radicals; Lipid Peroxides; Male; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type III; Ramipril; Renin-Angiotensin System; Telmisartan

2011
Telmisartan in high-risk cardiovascular patients. No need to change standard practice.
    Prescrire international, 2011, Volume: 20, Issue:117

    Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Ramipril; Risk Factors; Telmisartan

2011
New clinical concepts after the ONTARGET trial.
    Expert review of cardiovascular therapy, 2011, Volume: 9, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Ramipril; Telmisartan

2011
Prevention and intervention studies with telmisartan, ramipril and their combination in different rat stroke models.
    PloS one, 2011, Volume: 6, Issue:8

    Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Male; Ramipril; Random Allocation; Rats; Rats, Inbred SHR; Rats, Wistar; Stroke; Telmisartan

2011
The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.
    Journal of medical economics, 2011, Volume: 14, Issue:6

    Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Cardiovascular Diseases; Cost of Illness; Diabetes Complications; Health Services; Heart Failure; Humans; Multicenter Studies as Topic; Myocardial Infarction; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Telmisartan

2011
Is a blood pressure target of <130/80 mm Hg still appropriate for high-risk patients?
    Circulation, 2011, Oct-18, Volume: 124, Issue:16

    Topics: Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Guidelines as Topic; Humans; Kidney Diseases; Ramipril; Telmisartan

2011
Double blockade of angiotensin II (AT(1) )-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats.
    British journal of pharmacology, 2012, Volume: 165, Issue:8

    Topics: Adipose Tissue; Adrenocorticotropic Hormone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Corticosterone; Drug Therapy, Combination; Feeding Behavior; Heart Rate; Leptin; Male; Obesity; Ramipril; Rats; Rats, Inbred SHR; Telmisartan; Weight Gain

2012
A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy.
    The Indian journal of medical research, 2011, Volume: 134, Issue:5

    Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pilot Projects; Ramipril; Telmisartan

2011
[High blood pressure in the morning].
    MMW Fortschritte der Medizin, 2011, Dec-08, Volume: 153, Issue:49-50

    Topics: Benzimidazoles; Benzoates; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Delayed-Action Preparations; Drug Combinations; Drug Substitution; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Ramipril; Telmisartan

2011
Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs.
    Journal of cardiovascular pharmacology and therapeutics, 2013, Volume: 18, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Blood Pressure; Cardiomegaly; Drug Therapy, Combination; Endothelial Cells; Fibrosis; Male; Mice; Mice, Inbred C57BL; Myocardium; Ramipril; Stem Cells; Telmisartan

2013
Is there room for dual blockade of the renin-angiotensin-aldosterone system?
    Journal of hypertension, 2012, Volume: 30, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Humans; Ramipril; Renin-Angiotensin System; Telmisartan

2012
Prediction and prevention of atrial fibrillation in patients with high blood pressure or history of hypertension.
    Journal of hypertension, 2012, Volume: 30, Issue:5

    Topics: Atrial Fibrillation; Benzimidazoles; Benzoates; Cardiovascular Diseases; Female; Humans; Male; Ramipril; Telmisartan

2012
Renal outcome in equipotent antihypertensive treatment with telmisartan, ramipril and in combination in SHR-SP rats.
    Clinical laboratory, 2012, Volume: 58, Issue:7-8

    Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Body Weight; Drug Therapy, Combination; Kidney Function Tests; Organ Size; Ramipril; Rats; Rats, Inbred SHR; Survival Rate; Telmisartan

2012
[Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
    Deutsche medizinische Wochenschrift (1946), 2012, Volume: 137, Issue:48

    Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Coronary Vasospasm; Drug Therapy, Combination; Early Termination of Clinical Trials; Fumarates; Humans; Hypertension; Ramipril; Randomized Controlled Trials as Topic; Renin; Renin-Angiotensin System; Telmisartan

2012
Etoricoxib attenuates effect of antihypertensives in a rodent model of DOCA-salt induced hypertension.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2013, Volume: 35, Issue:8

    Topics: Animals; Antihypertensive Agents; Atenolol; Benzimidazoles; Benzoates; Blood Pressure; Cyclooxygenase 2 Inhibitors; Desoxycorticosterone Acetate; Disease Models, Animal; Etoricoxib; Hypertension; Mineralocorticoids; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Sodium Chloride; Sulfones; Telmisartan

2013
Acute regulation of pancreatic islet microcirculation and glycaemia by telmisartan and ramipril: discordant effects between normal and type 2 diabetic rats.
    Clinical science (London, England : 1979), 2013, Volume: 125, Issue:9

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Blood Glucose; Diabetes Mellitus, Type 2; Insulin; Islets of Langerhans; Male; Microcirculation; Pancreas; Ramipril; Rats; Rats, Wistar; Regional Blood Flow; Renin-Angiotensin System; Telmisartan

2013
Moving dietary management of diabetes forward.
    JAMA internal medicine, 2013, Oct-14, Volume: 173, Issue:18

    Topics: Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Diet; Feeding Behavior; Female; Humans; Male; Ramipril; Renal Insufficiency, Chronic; Telmisartan

2013
[Effect of RAAS antagonist on the expression of gap junction cx43 in myocardium of spontaneously hypertensive rat].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2013, Volume: 44, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Connexin 43; Eplerenone; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Ramipril; Rats; Rats, Inbred SHR; Rats, Wistar; Renin-Angiotensin System; Spironolactone; Telmisartan

2013
Systolic blood pressure target levels: evidence for benefits in stroke.
    Hypertension (Dallas, Tex. : 1979), 2015, Volume: 65, Issue:1

    Topics: Benzimidazoles; Benzoates; Blood Pressure; Coronary Artery Disease; Female; Humans; Male; Myocardial Infarction; Ramipril; Stroke; Telmisartan

2015
Recent clinical trials.
    Journal of the American Society of Hypertension : JASH, 2014, Volume: 8, Issue:10

    Topics: Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypertension; Ramipril; Randomized Controlled Trials as Topic; Telmisartan

2014
Single-pill combination therapy in the initial treatment of marked hypertension: a propensity-matched analysis.
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2015, Volume: 37, Issue:5

    Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Dihydropyridines; Dose-Response Relationship, Drug; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Perindopril; Propensity Score; Ramipril; Retrospective Studies; Risk Factors; Telmisartan; Tetrazoles

2015
Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk.
    Hypertension (Dallas, Tex. : 1979), 2015, Volume: 65, Issue:3

    Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Cognition Disorders; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Rate; Humans; Hypertension; Incidence; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Ramipril; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Telmisartan

2015
Use of Health Care Databases to Support Supplemental Indications of Approved Medications.
    JAMA internal medicine, 2018, 01-01, Volume: 178, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Delivery of Health Care; Drug Approval; Drug Prescriptions; Follow-Up Studies; Humans; Ramipril; Retrospective Studies; Telmisartan; United States

2018
Lung and Kidney ACE2 and TMPRSS2 in Renin-Angiotensin System Blocker-Treated Comorbid Diabetic Mice Mimicking Host Factors That Have Been Linked to Severe COVID-19.
    Diabetes, 2021, Volume: 70, Issue:3

    Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; COVID-19; Diabetes Mellitus, Experimental; Diet, High-Fat; Immunoblotting; In Situ Hybridization; Kidney; Lung; Male; Mice; Ramipril; Receptors, Coronavirus; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Serine Endopeptidases; Telmisartan

2021
Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic.
    Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2022, Volume: 166, Issue:3

    Topics: Angiotensin II Type 2 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Antihypertensive Agents; Czech Republic; Heart Failure; Humans; Losartan; Neprilysin; Perindopril; Ramipril; Retrospective Studies; Telmisartan; Valsartan

2022
Effects of ACE inhibitors and angiotensin receptor blockers: protocol for a UK cohort study using routinely collected electronic health records with validation against the ONTARGET trial.
    BMJ open, 2022, 03-08, Volume: 12, Issue:3

    Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Clinical Trials as Topic; Cohort Studies; Drug Therapy, Combination; Electronic Health Records; Ethnicity; Humans; Minority Groups; Ramipril; Telmisartan; United Kingdom

2022
Medicine-Induced Acute Kidney Injury Findings from Spontaneous Reporting Systems, Sequence Symmetry Analysis and a Case-Control Study with a Focus on Medicines Used in Primary Care.
    Drug safety, 2022, Volume: 45, Issue:11

    Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Amlodipine; Amphotericin B; Australia; Case-Control Studies; Ciprofloxacin; Diclofenac; Furosemide; Humans; Ibuprofen; Metformin; Naproxen; Omeprazole; Primary Health Care; Ramipril; Simvastatin; Spironolactone; Sulfamethoxazole; Telmisartan; Trimethoprim; Valacyclovir; Zoledronic Acid

2022